Loading clinical trials...

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer | Clinical Trials | Clareo Health

TERMINATED

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell

NCT01591512•Fujirebio Diagnostics, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to collect samples to evaluate the ProGRP and NSE assays independently as aids for monitoring the course of disease and therapy in subjects diagnosed with SCLC.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥ 18
•Confirmed diagnosis of SCLC or mixed SCLC/non-SCLC per histopathology results
•Scheduled to undergo first-, second- or third-line treatment for SCLC, including chemotherapy, chemotherapy + radiation therapy, or combined concurrent chemoradiotherapy.
•Able to understand and willing to provide Informed Consent

Exclusion Criteria

•No diagnosis of SCLC
•Not scheduled to undergo treatment for the diagnosis of SCLC
•Unable to provide Informed Consent

Locations (4)

Kelly Family Medical Center, PC

Eastpointe, Michigan, United States

St.Louis Cancer Care, LLP

Bridgeton, Missouri, United States

Heartland Regional Medical Center

Saint Joseph, Missouri, United States

Hematology Oncology Consultants, Inc.

St Louis, Missouri, United States

Key Dates

Start Date

May 1, 2011

Primary Completion Date

July 1, 2012

Completion Date

July 1, 2012

Last Updated

March 6, 2015

Enrollment

ACTUAL participants

Conditions

Small Cell Lung Cancer

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGPHASE3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)